F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 February 2017 - 31 January 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 February 2017 - 31 January 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the WFC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

87 43.45 43.45

Outputs by subject (WFC)

Subject AC FC WFC
Life Sciences 58 28.16 28.16
Chemistry 33 17.96 17.96
Physical Sciences 1 0.02 0.02

Highlight of the month

Molecular holograms light up biosensing

© MyFortis/DigitalVision Vectors/Getty

© MyFortis/DigitalVision Vectors/Getty

A new biosensing technique known as focal molography enables researchers to study the interactions of biological molecules in real time without labelling or extensive sample preparation. The technique was invented at Roche several years ago, but has only now been demonstrated in practice.

Biosensors typically involve binding the target molecules to a substrate and then washing off unwanted molecules before detection. In focal molography, the binding substrate is arranged in a specific striped pattern on a chip. A laser is then shined along the chip. If the target molecules are bound to the stripes, the beam diffracts and focuses on a single point on the detector; without target molecules, there is no diffraction and no signal. Non-target molecules do not cause diffraction, making the technique extremely specific.

Focal molography will facilitate studies of biomolecule secretion, cell-cell communication, and other subjects, and may eventually underlie the technology for a handheld diagnostic tool.

Supported content

  1. Nature Nanotechnology 12, 1089–1095 (2018). doi: 10.1038/nnano.2017.168

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 February 2017 - 31 January 2018

International vs. domestic collaboration by WFC

  • 7.31% Domestic
  • 92.69% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the weighted fractional count (WFC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs